TET2 and myelodysplastic syndrome: TET2 mutations were found in 17% of patients with MDS, 46% of MDS/myeloproliferative neoplasms, 19% of myeloproliferative neoplasms, 21% of primary AMLs and 20% of treatment-related myeloid neoplasia.